<DOC>
	<DOCNO>NCT01162954</DOCNO>
	<brief_summary>This double-blind , randomize , placebo-controlled , 4-period , cross-over clinical trial . The study design evaluate safety local tolerability DA-6034 upon single repeated-dose topical application eye healthy volunteer .</brief_summary>
	<brief_title>Phase I Study Evaluate Tolerability Eye Drop DA-6034 Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>2050 yearold healthy subject Presence history dry eye ocular systemic disease Corrected visual acuity le 20/40 either eye screen Any eye surgery laser eye surgery within past six month Intraocular pressure great 22 mmHg either eye screen Breakup time le 10 sec OSDI score correspond mild severe dry eye symptom either eye screen Unanesthetized Schirmer score &lt; 10 mm either eye screening</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Eye drop , Dry eye</keyword>
</DOC>